China Resources Sanjiu Medical & Pharmaceutical Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	5.1yrs
Promedio de permanencia en la Junta Directiva	4.2yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

China Resources Sanjiu Medical & Pharmaceutical no tiene CEO, o no tenemos datos al respecto.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Wen Duo Wu	President & Director	less than a year	CN¥1.88m	sin datos
Zheng Liang	CFO & Secretary of the Board of Directors	5.1yrs	CN¥2.49m	0.013% CN¥ 7.5m
Hui Zhou	VP, General Counsel	13.3yrs	CN¥3.10m	0.013% CN¥ 7.7m
Liang Wang	Vice President	no data	CN¥2.67m	0.010% CN¥ 5.8m

5.1yrs

Permanencia media

47.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 000999 es experimentado (5.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Wen Duo Wu	President & Director	less than a year	CN¥1.88m	sin datos
Hui Zhou	VP, General Counsel	19.6yrs	CN¥3.10m	0.013% CN¥ 7.7m
Huawei Qiu	Chairman	7.2yrs	CN¥4.61m	0.019% CN¥ 11.2m
Fang Xu	Independent Director	6.6yrs	CN¥150.00k	sin datos
Xingtian Yao	Independent Director	6.6yrs	CN¥150.00k	sin datos
Ran Tao	Chairman of the Supervisory Board	6yrs	sin datos	sin datos
Na Tang	Non-Employee Supervisor	5.4yrs	sin datos	sin datos
Qiang Zhang	Independent Director	1.2yrs	sin datos	sin datos
Xiaosong Bai	Non-Independent Director	2.7yrs	sin datos	sin datos
Xingpin Cui	Non-Independent Director	2.7yrs	sin datos	sin datos
Yang Don	Director	3yrs	CN¥150.00k	sin datos
Shutian Yu	Director	2.1yrs	sin datos	sin datos

4.2yrs

Permanencia media

56yo

Promedio de edad

Junta con experiencia: La junta directiva de 000999 se considera experimentada (4.2 años de antigüedad promedio).

China Resources Sanjiu Medical & Pharmaceutical Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

High number of new directors

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

High number of new directors

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

High number of new directors

High number of new directors

Recent updates

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Proposes Profit Distribution Plan for the Third Quarter of 2024

Third quarter 2024 earnings released: EPS: CN¥0.45 (vs CN¥0.41 in 3Q 2023)

Investor sentiment improves as stock rises 25%

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment deteriorates as stock falls 17%

Second quarter 2024 earnings released: EPS: CN¥0.80 (vs CN¥0.57 in 2Q 2023)

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

Dividend increased to CN¥1.50

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 14 June 2024

High number of new directors

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Full year 2023 earnings released: EPS: CN¥2.90 (vs CN¥2.48 in FY 2022)

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 23, 2024

Third quarter 2023 earnings released: EPS: CN¥0.53 (vs CN¥0.53 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.75 (vs CN¥0.60 in 2Q 2022)

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Announces Implementation of Cash Dividend for 2022, Payable on 15 June 2023

Now 22% undervalued

Full year 2022 earnings released: EPS: CN¥2.48 (vs CN¥2.09 in FY 2021)

Now 20% undervalued

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Year Ended 31 December 2022

Investor sentiment improved over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.53 (vs CN¥0.39 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.60 (vs CN¥0.73 in 2Q 2021)

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2021, Payable on 12 August 2022

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2021

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SZSE:000999) agreed to acquire 28% stake in KPC Pharmaceuticals, Inc. (SHSE:600422) from Holley Pharmaceutical Group Co., Ltd and Holley Group Company Limited for CNY 2.9 billion.

First quarter 2022 earnings released: EPS: CN¥0.86 (vs CN¥0.66 in 1Q 2021)

High number of new directors

High number of new directors

Investor sentiment improved over the past week

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Proposes Cash Dividend as of 31 December 2021

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Announces Board Elections

High number of new directors

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.39 (vs CN¥0.51 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.73 (vs CN¥0.54 in 2Q 2020)

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Approves Final Cash Dividend for 2020

First quarter 2021 earnings released: EPS CN¥0.66 (vs CN¥0.54 in 1Q 2020)

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Proposes Cash Dividend for the Year December 31, 2020

Full year 2020 earnings released: EPS CN¥1.63 (vs CN¥2.16 in FY 2019)

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 19, 2021

New 90-day low: CN¥24.96

Third quarter earnings released

Third-quarter earnings released: Revenue misses expectations

New 90-day low: CN¥26.02

New 90-day low - CN¥27.00

Earnings released

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 26, 2020

CEO

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad